News NWO Top Grant for Ulrich Brandt

1 February 2018

Ulrich Brandt, theme Mitochondrial diseases received a NWO Top grant of € 780,000 for a project entitled: Molecular mechanism and regulation of energy conversion by mitochondrial complex I.

The complexes of oxidative phosphorylation are the major energy converters of aerobic cells that are also involved in multiple other cellular processes. Complex I (NADH:ubiquinone oxidoreductase) is the largest and most complicated respiratory chain enzyme. It is a major source of reactive oxygen species and in man prominently involved in inherited mitochondrial diseases, neurodegenerative disorders and aging. Despite its tremendous biomedical importance, there is large gap of knowledge, when it comes to the mechanism and regulation of mitochondrial complex I. The recently solved bacterial and mitochondrial X-ray structures launch a new phase in complex I research by finally providing the blueprints of this fascinating molecular machine that were desperately needed to unravel its intricate molecular mechanism. Our X-ray structure of mitochondrial complex I and our structure/function studies provided fundamental insights into the design and dynamics of the ubiquinone-binding pocket. It led us to propose an integrated mechanistic model for catalysis and regulation of complex I. Using this hypothesis as a starting point, we will elucidate the still enigmatic molecular mechanism of complex I and its poorly understood regulation by the so-called active/deactive (A/D) transition. Specifically we aim at defining the catalytic and regulatory sub-states of complex I and how they control the chemistry of ubiquinone intermediates by a combination of advanced, mutagenesis based structure/function analysis and structural analysis.

Specifically, we will work out in detail the “mechanics” of the conformational changes by which the charge induced reorganiza¬tion of the ubiquinone binding site leads to the generation of the power stroke transmitted into the membrane arm to drive proton pumping. To this end, we will probe the loop rearrangements within the ubiquinone binding pocket to decipher their workings during catalytic turnover and the A/D transition. Furthermore, we will define the structural features controlling the chemistry of ubiquinone in the different functional states of mitochondrial complex I. Finally, we aim at understanding, how the mechanism of energy conversion of complex I is controlled by the A/D transition at the molecular level.

We expect that at the end of the funding period we can present a refined and experimentally well supported molecular mechanism of energy conversion that integrates the different func¬tional modes of mitochondrial complex I. Although the focus of the proposed study is exclusively on fundamental research, the results will have broad biomedical impact, since complex I dysfunction has been implicated in numerous human pathologies, including inherited mitochondrial disease, M. Parkinson, M. Alzheimer, ischemia/ reperfusion injuries and biological ageing.
 
 
 

 

Related news items


Christine Mohrmann stipendium for Karlien Mul

14 December 2018

The goal of the stipendium is to enable junior female scientists to perform research abroad and to encourage them to pursue a scientific career in academia.

read more

Call for nominations RIHS Awards 2017 & 2018

14 December 2018

RIHS researchers are invited to propose candidates for the RIHS PhD Award, the Societal Impact Award, the Science Award and the Supervisor of the year Award. Deadline for nominations is 14 January 2019.

read more

Bart Kiemeney among most cited researchers

13 December 2018

Bart Kiemeney made it to this year’s list of highly cited researchers. Researchers in this list are selected for their exceptional research performance and are regarded to have had a major impact on fellow scientists.

read more

Metal surgical implants can activate drugs

13 December 2018

Marja Bulte-ter Meer and Leo Schultze Kool discovered that the iron in metal surgical implants can activate drugs such as antibiotics, thus enabling targeted therapy.

read more

A personal touch of Dimitri Diavatopoulos

13 December 2018

In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t! This week: Dimitri Diavatopoulos.

read more

Annual CaRe days 8 & 9 May 2019

13 December 2018

The CaRe days provides an inspiring program for all RIHS researchers. Save the date!

read more
  • Go to